---
created: 2025-04-13
updated: 2025-04-13T10:51
id: g-)Y{j:CCP
specialty: cardio
specialty_id: 183
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - source/ak-step1-v11::
  - theme/b&b::03-biochem::05-lipids::03-lipid-drugs
  - source/ak-step1-v11::
  - theme/firstaid::07-cardiovascular::05-pharm::10-lipid-lowering-agents::statins
  - source/ak-step1-v11::
  - source/ome-banner::basic-science::09-cardiac
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::10-cardiac::09-statins
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::06-cardio::hmg-coa-reductase-inhibitors-(statins)
  - source/ak-step1-v11::
  - theme/sketchypharm::03-blood-&-inflammation::02-dyslipidemia-drugs::01-statins
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - source/ak-step1-v11::^systems::cardio::pharmacology"
type: flashcard
---

# Question
**Statins::HMG-CoA reductase inhibitors** are the most effective lipid lowering medications for preventing future cardiovascular events

---

# Answer
initiated in the setting of MI and other acute coronary syndromes; drugs that raise HDL (e.g. niacin) are not associated with improved cardiac outcomes